FP-1039 - Five Prime
Five Prime Therapeutics: J.P. Morgan Healthcare Conference (Five Prime Therap) - Jan 14, 2016 - Anticipated data from P1b trial (NCT01868022) in 1L and previously-treated squamous NSCLC and 1L mesothelioma at ASCO (Jun 3-7, 2016) 
Anticipated P1 data Non Small Cell Lung Cancer • Oncology
http://files.shareholder.com/downloads/AMDA-24F834/968544019x0x870042/4138AADD-E05D-4FE0-B45F-C8F89BD069F0/Five_Prime_J.P._Morgan_Corporate_Overview_2016_v2.pdf
 
Jan 14, 2016
 
.
 
ee6651a3-b860-43a7-9a85-ece29cc80dad.jpg